Celecoxib Topical Nanoemulgel: Formulation, Ex-Vivo, Pharmacodynamic, and Pharmacokinetic Studies

Abstract

Celecoxib is a COX-2 inhibitor used for anti-inflammatory activity and to reduce the oral side effects, it is formulated in topical gel form. The method used for the development of the emulsomes was emulsion solvent diffusion method. The formulated celecoxib emulsomes were optimized, and the optimized celecoxib emulsomes were converted into topical gel. The physicochemical properties like SEM, DSC, FT-IR, results indicate that there is no chemical interaction between the drug and polymer. The zeta potential, particle size, entrapment efficiency of the optimized emulsomes were found to be 119.3252 nm and –16.3 mV. Optimized X1 gel by physical examination appears to be homogenous, with pH 7 ± 0.2 and viscosity 8,640cps, and with 98.3% of drug content. The cumulative percentage of drug release was found both between the in-vivo and ex-vivo levels and ex-vivo skin permeation studies found that the release was 95% for 4 h. The gels that were prepared were subjected to pharmacokinetic and pharmacodynamic studies. The in-vivo pharmacokinetic and dynamic results showed that the emulsomal gel has shown effective inhibition of inflammation. The significant activity (p < 0.05) was exhibited by Celecoxib-loaded emulsomal gel when it is compared to the marketed formulation (Voveran Emulgel).